Another observation I had looking at the poster presentation - If recruiting continues up to 500 patients in the MoCA arm and the patients are expected to be in the arm for at least 6 months then there is a reasonable chance that we will not see any Alzheimer's data in the Top Line Results. All patients in this arm get a MoCA to start, at the end of 1 year, annually and at the end of the trial. This suggests that all 500 patients will need to have their final MoCA after the 250th event and then have that data delivered and deciphered before it is able to be reported. We could of course see data for some of the patients who had a one year or even two year MoCA. Unless this process has dramatically spread up in the last 5 yrs we will be waiting for that for a time after the Top Line Results are out. I'd be more than happy to be dead wrong on this.

Biogen was up another 4% this morning after presenting at the AAIC in Chicago. What would happen to our market cap if we were to show a double digit increase in cognitive function in this MoCA arm of BETonMACE?

All IMO dyodd 

tada